AMENDMENTS TO THE CLAIMS

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-18. (Cancelled)

19. (Currently amended) A method for prevention of chronic refractory graft rejection in a human lung transplant recipient comprising administering to the recipient, ~~within 10 days following transplantation or~~ prior to the development of symptoms associated with transplant rejection, (i) an aerosolized composition comprising:

~~(i) a~~ a therapeutic dose of ~~non-encapsulated~~ cyclosporine ~~in an amount effective to prevent graft rejection;~~

~~(ii) and a propellant~~ and (ii) an effective amount of one or more other immunosuppressive agent.

20. (Currently amended) The method of claim 19, wherein the cyclosporine is administered as ~~A method for prevention of graft rejection in a lung transplant recipient comprising administering to the recipient, within 10 days following transplantation or prior to the development of symptoms associated with transplant rejection, an aerosolized composition comprising:~~

~~(i) a dose of non-encapsulated cyclosporine in an amount effective to prevent graft rejection;~~

~~(ii)~~ a dry powder~~; and~~ in combination with

~~(iii)~~ a propellant.

21. (Currently amended) The method of claim 19, wherein the cyclosporine is dissolved in ~~A method for prevention of graft rejection in a lung transplant recipient comprising administering to the recipient, within 10 days following transplantation or prior to the development of symptoms associated with transplant rejection, an aerosolized composition comprising :~~

~~(i) a dose of non-encapsulated cyclosporine in an amount effective to prevent graft rejection;~~

~~(ii)~~ an organic solvent~~; and~~

~~(iii) a propellant~~.

22. (Previously presented) The method of claim 19, 20 or 21 wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 15 and 30 mg in a lung.

23. (Cancelled)

24. (Currently amended) The method of claim 19, 20 or 21 wherein the aerosolized composition is co-administered with [[a]] an anti-inflammatory reagent.

25. (Currently amended) A method for ameliorating pulmonary inflammation in a subject having a lung disorder selected from the group consisting of asthma, sarcoidosis, emphysema, cystic fibrosis, idiopathic pulmonary fibrosis, chronic bronchitis, hypersensitivity pneumonitis and eosinophilic pneumonia, comprising administering to the subject an aerosolized composition comprising~~:~~

~~(i)~~ a dose of ~~non-encapsulated~~ cyclosporine dissolved in an organic solvent, in an amount effective to inhibit or ameliorate pulmonary inflammation~~; and~~

~~(ii) a propellant~~.

26. (Currently amended) A method for ameliorating pulmonary inflammation in a subject comprising administering to the subject an aerosolized composition comprising :

(i) a dose of ~~non-encapsulated~~ cyclosporine in dry powder form in an amount effective to inhibit or ameliorate pulmonary inflammation; and

(ii) ~~a dry powder; and~~

~~(iii)~~ a propellant.

27. (Cancelled)

28. (Cancelled)

29. (Currently amended) The method of claim 25[[,]] or 26 ~~or 27~~ wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 5 and 30 mg in a lung.

30. (Currently amended) A method for prevention of graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient, ~~within 10 days following transplantation or~~ prior to the development of symptoms associated with transplant rejection, an aerosolized composition comprising~~:~~

~~(i) a~~ a dose of ~~non-encapsulated~~ cyclosporine dissolved in an organic solvent, in an amount effective to prevent graft rejection~~;~~

~~(ii) and a propellant~~.

31. (Currently amended) A method for prevention of graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient, ~~within 10 days following transplantation or~~ prior to the development of symptoms associated with transplant rejection, an aerosolized composition comprising :

(i) a dose of ~~non-encapsulated~~ cyclosporine in dry powder form in an amount effective to prevent graft rejection; and

(ii) ~~a dry powder; and~~

~~(iii)~~ ~~and~~ a propellant.

32. (Cancelled)

33. (Currently amended) A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject, where said disorder is selected from the group consisting of type IV cell-mediated hypersensitivity, systemic lupus erythematosis, myasthenia gravis, Grave's disease, Hashimoto's thyroiditis, rheumatoid arthritis, scleroderma, and pernicious anemia, comprising administering, to the subject, ~~to the non-lung transplant recipient, within 10 days following transplantation or prior to the development of symptoms associated with transplant rejection,~~ an aerosolized composition comprising:

~~(i)~~ a dose of ~~non-encapsulated~~ cyclosporine dissolved in an organic solvent, in an amount effective to inhibit the immune response associated with a T-cell mediated immune disorder~~; and~~

~~(ii) a propellant~~.

34. (Currently amended) The method of claim 30[[,]] or 31 ~~or 32~~ wherein the dose of cyclosporine is sufficient to achieve circulating levels ranging between 50-250 ng/ml.

35. (Currently amended) The method of claim 30[[,]] or 31 ~~or 32~~ wherein the aerosolized composition is co-administered with a second immunosuppressive agent.

36. (Currently amended) A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject subject, where said disorder is selected from

the group consisting of type IV cell-mediated hypersensitivity, systemic lupus erythematosis, myasthenia gravis, Grave's disease, Hashimoto's thyroiditis, rheumatoid arthritis, scleroderma, and pernicious anemia, comprising administering to the subject ~~non-lung transplant recipient, within 10 days following transplantation or prior to the development of symptoms associated with transplant rejection,~~ an aerosolized composition comprising:

(i) a dose of ~~non-encapsulated~~ cyclosporine in dry powder form in an amount effective to inhibit the immune response associated with a T-cell mediated immune disorder; and

(ii) ~~a dry powder; and~~

~~(iii)~~ a propellant.

37-48. (Cancelled)